Registry for young-onset diabetes and its genetic factors
Optimized Diagnosis and Precision Medicine of MODY (Maturity-Onset Diabetes of the Young)
This study is creating a registry for young people with diabetes to see how different types of the condition, especially MODY, affect their health and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Taichung Veterans General Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Taichung) |
| Trial ID | NCT06111833 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive registry for young-onset diabetic patients, focusing on Maturity-Onset Diabetes of the Young (MODY) and its various subtypes. It will collect detailed clinical data, including health history, medication use, and family history, along with biological samples for genetic testing. The study will analyze the distribution of MODY types, their clinical characteristics, and responses to antidiabetic medications. By understanding the genetic underpinnings and clinical manifestations, the research seeks to improve precision medicine approaches for young-onset diabetes.
Who should consider this trial
Good fit: Ideal candidates include young-onset diabetic patients diagnosed at or before 25 years of age, with a BMI of 25 kg/m² or lower and a family history of type 2 diabetes.
Not a fit: Patients diagnosed with type 1 diabetes or those under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and tailored treatments for young-onset diabetic patients, improving their health outcomes.
How similar studies have performed: While there have been studies on diabetes and genetic factors, this specific approach focusing on young-onset diabetes and MODY is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg/m² or lower. Having at least one parent diagnosed with type 2 diabetes. 2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects. Expressing willingness to participate in this study after granting informed consent. 3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics. At least one parent has been diagnosed with type 2 diabetes. Exclusion Criteria: 1. Confirmed Diagnosed with type 1 diabetes. 2. Under 18 years of age. 3. Unable to personally provide informed consent. 4. Patients with unrelieved leukemia. 5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months. 6. Cases that have received a blood transfusion within the last six months. 7. Unwilling or unable to continue treatment follow-up at this hospital.
Where this trial is running
Taichung
- Taichung veterans general hospital — Taichung, Taiwan (Recruiting)
Study contacts
- Principal investigator: Yi-Jing Sheen, MD. PHD — Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
- Study coordinator: Yi-Jing Sheen, MD. PHD
- Email: docmedjean@gmail.com
- Phone: 886-4-2359-2525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.